Gilead Sciences (NASDAQ:GILD) Given Hold Rating at Robert W. Baird

Robert W. Baird restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note released on Thursday morning, TipRanks reports. Robert W. Baird currently has a $75.00 price objective on the biopharmaceutical company’s stock.

GILD has been the topic of several other reports. Oppenheimer restated a buy rating on shares of Gilead Sciences in a research report on Monday. BidaskClub cut Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday. Wells Fargo & Co restated a hold rating and issued a $84.00 target price on shares of Gilead Sciences in a research report on Friday, May 1st. JPMorgan Chase & Co. restated a hold rating and issued a $85.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 13th. Finally, Morgan Stanley raised their target price on Gilead Sciences from $75.00 to $77.00 and gave the company an equal weight rating in a research report on Friday, May 1st. Seven equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $78.15.

Shares of NASDAQ GILD traded down $0.16 during mid-day trading on Thursday, hitting $73.34. The company had a trading volume of 6,235,402 shares, compared to its average volume of 20,370,521. The stock has a market cap of $91.85 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 3.16 and a beta of 0.72. Gilead Sciences has a 12 month low of $60.89 and a 12 month high of $85.97. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92. The firm’s 50 day simple moving average is $77.81 and its two-hundred day simple moving average is $70.11.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.11. The business had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business posted $1.67 EPS. Equities analysts forecast that Gilead Sciences will post 6.34 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Friday, June 12th will be given a $0.68 dividend. The ex-dividend date of this dividend is Thursday, June 11th. This represents a $2.72 annualized dividend and a dividend yield of 3.71%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.

In related news, Director John Francis Cogan sold 2,413 shares of Gilead Sciences stock in a transaction on Monday, March 9th. The stock was sold at an average price of $77.97, for a total transaction of $188,141.61. Following the completion of the sale, the director now owns 57,273 shares of the company’s stock, valued at $4,465,575.81. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Brett A. Pletcher sold 10,441 shares of Gilead Sciences stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $70.88, for a total value of $740,058.08. Following the sale, the executive vice president now directly owns 25,085 shares of the company’s stock, valued at approximately $1,778,024.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,585 shares of company stock valued at $4,671,283. 0.13% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baldwin Brothers Inc. MA boosted its position in Gilead Sciences by 63.3% during the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 136 shares during the last quarter. TRUE Private Wealth Advisors bought a new position in Gilead Sciences during the fourth quarter valued at about $25,000. Bainco International Investors bought a new position in Gilead Sciences during the first quarter valued at about $29,000. Pin Oak Investment Advisors Inc. bought a new position in Gilead Sciences during the fourth quarter valued at about $26,000. Finally, EPG Wealth Management LLC raised its holdings in Gilead Sciences by 186.7% during the first quarter. EPG Wealth Management LLC now owns 410 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 267 shares in the last quarter. 77.34% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Short Selling

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.